Compare Regeneron Pharmaceuticals Inc (REGN) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs SoundHound AI Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $750.28 (market cap $76.14B), while SoundHound AI Inc trades at $5.43 (market cap $2.45B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 31.1× SoundHound AI Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and SoundHound AI Inc for 23 Days on average.
| REGN | SOUN | |
|---|---|---|
Market Cap | $76.14B | $2.45B |
Volume | 500,239 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $852.03 | $21.40 |
52-Week Low | $557.73 | $5.52 |
Typical Hold Time | 107 Days | 23 Days |
Enterprise Value | $70.85B | $2.25B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
SoundHound AI (SOUN) trades at $5.49, down 2.49% today, with bearish technical signals but strong analyst support. The company shows robust revenue growth with 2025 revenue of $168.92M and 2026 projected at $203M, though it remains unprofitable with a -67.45% net margin. Recent developments include expansion in restaurant and banking sectors with voice AI technology, while technical indicators show oversold conditions with RSI at 25-29.
The outlook remains speculative with significant execution risk despite 75% analyst buy ratings and a $9.33 consensus target. Key opportunities include voice AI market expansion and enterprise contract wins, while risks center on persistent losses, high valuation multiples, and competitive pressures in the AI sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
